Skip to content
DataLookout
Menu

NCT07932925

The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight

StatusNot Yet Recruiting
PhasePhase 3
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change From Baseline in Stress Incontinence Episode Frequency (IEF)
Timeframe: Baseline, Week 52

Secondary (7)

Percent Change From Baseline in Body Weight
Percent change from baseline in Stress Incontinence Episode Frequency
Change from Baseline in Urinary Incontinence-Specific Quality of Life as assessed by the Quality-of-Life Instrument (QOL)
Change from Baseline in Fasting Lipids
Change From Baseline in weight
Show 2 moreShow less
Change From Baseline in waist circumference
Number of participants with Treatment-Emergent Adverse Event (TEAE)

Arms and interventions

Arm 1Active comparator

Participants will receive Berobenatide administered according to the study dosing regimen

Arm 2Placebo comparator

Participants will receive placebo administered according to the study dosing regimen

Drugs: Berobenatide, Placebo